Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial

Conclusions[18F]DCFPyL PET/CT increases detection of disease in patients with biochemical recurrence post prostatectomy compared to diagnostic CT. Patients being considered for salvage radiotherapy with a PSA>0.2  ng/mL should be considered for [18F]DCFPyL PET/CT scan.Trial registrationAustralian New Zealand Clinical Trials Registry Number: ACTRN12618001530213 (http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375932&isReview=true)
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research